Nutromics
Nutromics develops minimally invasive, wearable biosensor solutions for real-time, continuous monitoring of molecular biomarkers and therapeutic drugs. The company's platform technology integrates DNA-based electrochemical sensors with microneedles, aiming to transform current diagnostic practices by enabling continuous molecular measurements directly from patients. Nutromics is focused on therapeutic drug monitoring and broader critical care indications, with ongoing clinical studies and regulatory development. Its interdisciplinary team operates from Melbourne and San Diego, supported by collaborations with leading academic partners.
Industries
N/A
Nutromics
Melbourne, Victoria, Australia; San Diego, California, USA
Products
A minimally invasive, wearable patch integrating DNA-based electrochemical sensors and microneedles to enable real-time measurement of drugs and biomarkers in interstitial fluid.
A minimally invasive, wearable patch integrating DNA-based electrochemical sensors and microneedles to enable real-time measurement of drugs and biomarkers in interstitial fluid.
Expertise Areas
- Biosensing technology development
- Therapeutic drug monitoring
- Wearable diagnostics
- Minimally invasive medical devices
Key Technologies
- Electrochemical aptamer-based sensing
- Microneedle-based biosensors
- Multiplexed molecular detection
- Bluetooth-enabled data streaming
Key People
Co-Founder & CEO
Co-Founder & COO
Chief Financial Officer
Chairperson
Chief Product Development Officer
Head of People & Culture
Co-Founder & CEO
Co-Founder & COO
Chief Financial Officer
Chairperson
Chief Product Development Officer
Head of People & Culture
News & Updates
Awarded for innovation in biosensor platform technology.
Aptamer-coated microneedle patch detects antibiotic vancomycin in real time for over 12 hours.
Findings from a pilot trial of a wearable patch for continuous vancomycin measurement with clinical insights from Dr. Sophie Stocker.
Explores Nutromics’ biosensing platform for simultaneous, multi-analyte real-time tracking via wearable device.
Clinical trial demonstrated patch can accurately track antibiotic concentrations at 5-minute intervals.
Raised $7.5m, plans to build manufacturing facility in Australia.
Awarded for innovation in biosensor platform technology.
Aptamer-coated microneedle patch detects antibiotic vancomycin in real time for over 12 hours.
Findings from a pilot trial of a wearable patch for continuous vancomycin measurement with clinical insights from Dr. Sophie Stocker.
Explores Nutromics’ biosensing platform for simultaneous, multi-analyte real-time tracking via wearable device.
Clinical trial demonstrated patch can accurately track antibiotic concentrations at 5-minute intervals.
Raised $7.5m, plans to build manufacturing facility in Australia.